ASCO GU Conference Coverage

Genetic Gene Mutations: Opening New Therapeutic Avenues In Metastatic Prostate Cancer

(VHIO [Barcelona, Spain]) Feb 8, 2018 - DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. International study shows the prognostic and predictive value of these mutations in more precisely selecting standard therapies for the treatment of these patients.

read article

'Physician Trust' Tied to PSA Testing

(Medscape Medical News) Feb 9, 2018 - The level of trust a man has in his physician is "strongly associated" with the decision of whether to undergo prostate-specific antigen (PSA) screening, according to a new study of US attitudes and behaviors presented here at the Genitourinary Cancers Symposium (GUCS) 2018.

read article (free registration required)

Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC

(AJMC.com/Managed Markets Network) Feb 9, 2018 - Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to an abstract presented by Andrew Armstrong, MD, associate professor of medicine, Duke University School of Medicine, at the 2018 Genitourinary Cancers Symposium.

read article

ERLEADA (TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

(Janssen) Feb 8, 2018 - Phase 3 SPARTAN data showed ERLEADA™ improved median metastasis-free survival by more than two years. Data featured as oral presentation at ASCO GU 2018 (Abstract #161) and published in The New England Journal of Medicine.

read corporate press release

2018 Symposium Highlights Notable Research Advances in Genitourinary Cancers

(2018 Genitourinary Cancers Symposium) Feb 8, 2018 - Eight noteworthy studies exploring key research in the treatment of genitourinary cancers will be presented at the 2018 Genitourinary Cancers Symposium, taking place February 8-10 at the Moscone West Building in San Francisco, California.

read press release

Trimodal Therapy vs Radical Cystectomy for Patients With Localized Bladder Cancer

(Journal of Clinical Pathways) Feb 7, 2018 - Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.

read article

Clinical Value, Cost Considerations of Abiraterone Acetate, Enzalutamide in Prostate Cancer

(Journal Of Clinical Pathways) Feb 6, 2018 - A study to be presented at the 2018 ASCO Genitourinary Cancers Symposium (February 8-10, 2018; San Francisco, CA) applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale (MCBS) to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.

read article

Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors

(StreetInsider) Feb 7, 2018 - Exelixis, Inc. today announced updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.

read article

Cost-Effectiveness of Hydrogel Rectal Spacer in Radiotherapy for Prostate Cancer

(Journal of Clinical Pathways) Feb 8, 2018 - A cost-effectiveness analysis presented at the 2018 Genitourinary Cancers Symposium examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity modulated radiation therapy.

read article

Apalutamide Delays Progression Of Nonmetastatic, Castration-Resistant Prostate Cancer

(MGH) Feb 8, 2018 - A clinical trial led by investigators at Massachusetts General Hospital and University of California, San Francisco found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.

read press release

Myriad's myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation

(Myriad Genetics) Feb 7, 2018 - In results from a large 1,162 patient study of the Myriad myRisk® Hereditary Cancer test, more than 12 percent of men with prostate cancer had an inherited (i.e. hereditary) mutation in a cancer-causing gene.

read corporate press release

New Immunotherapy Combination Tolerable, Effective In Patients With Advanced Kidney Cancer

(GUMC) Feb 10, 2018 - Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated, according to a researcher at the Georgetown Lombardi Comprehensive Cancer Center who led this study.

read press release

Guidelines for Management of Muscle-Invasive Bladder Cancer

(AJMC.com/Managed Markets Network) Feb 9, 2018 - With new guidelines on how to treat and manage muscle-invasive bladder cancer, Jeffrey Holzbeierlein, MD, FACS, professor of urology, director of urologic oncology, interim chair of the department of urology, University of Kansas Health System, provided insight into how the guidelines have changed the management of the disease at the 2018 Genitourinary Cancers Symposium.

read article

Combo Therapy Highly Active in Untreated RCC

(MedPage Today) Feb 11, 2018 - Three-fourths of patients with newly diagnosed advanced renal cell carcinoma (RCC) had objective responses to the combination of axitinib (Inlyta) and pembrolizumab (Keytruda), a preliminary clinical trial showed.

read article (free registration required)

Survival Bump in Bladder Cancer with Keytruda

(MedPage Today) Feb 11, 2018 - Patients with recurrent urothelial cancer lived longer when they received pembrolizumab (Keytruda) instead of chemotherapy as second-line treatment, according to long-term follow of a randomized trial.

read article (free registration required)

'Cinderella' Cancer Gets Trial With Fairy-tale Ending?

(Medscape Medical News) Feb 12, 2018 - In a #GU18 Twitter poll, 62% of 73 respondents cited POUT as the "main practice change" presented at the meeting (the SPARTAN trial was a distant second, at 19%).

read article (free registration required)

Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years

(New York Times) Feb 8, 2018 - The treatments could help hundreds of thousands of men worldwide stave off pain and chemotherapy, but researchers don’t yet know if they will extend lives.

read article

BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium

(Morningstar) Feb 9, 2018 - BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, presented preliminary clinical data from patients with urothelial carcinoma (UC) enrolled in an ongoing Phase 1 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, at the 2018 Genitourinary Cancers Symposium in San Francisco.

read article

AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

(Morningstar) Feb 10, 2018 - AVEO Oncology and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC).

read article

Imaging Agent Can Change Plans for Recurrent Prostate Cancer

(Medscape Medical News) Feb 13, 2018 - Clinicians viewing scans using the imaging agent 18F-fluciclovine changed their management plans in 61% of cases of biochemical recurrence of prostate cancer.

read article (free registration required)
Next Page